http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
PhaseBio Pharmaceuticals Inc. (PHAS) Reports Successful Pre-BLA Meeting with the FDA for Bentracimab
-
PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights
-
PhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare Conference
-
PhaseBio Pharmaceuticals Inc. (PHAS) Reports Positive Results from Phase 2b Trial for Bentracimab
-
PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab
-
PhaseBio Pharmaceuticals Inc. (PHAS) Reports Q4 Results, Provides Recent Business Highlights
-
PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights
-
PhaseBio Pharmaceuticals Inc. (PHAS) Provides Update on Bentracimab Manufacturing
-
PhaseBio Pharmaceuticals Announces Bentracimab Manufacturing Update
-
PhaseBio Pharmaceuticals to Participate in the Cowen 42nd Annual Health Care Conference
-
PhaseBio Pharmaceuticals Inc. (PHAS) to Present Bentracimab Phase 2b Trial Data
-
PhaseBio Announces Bentracimab Phase 2b Trial Data Accepted for Late Breaking Clinical Research Presentation at the 2022 American College of Cardiology (ACC.22) Annual Scientific Session
-
PhaseBio Pharmaceuticals Inc. (PHAS) is voluntarily ending Phase 2b trial of pemziviptadil in PAH due to COVID-19 impacts on manufacturing
-
PhaseBio Provides Pemziviptadil (PB1046) Program Update
-
PhaseBio Pharmaceuticals Inc. (PHAS) Reports Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab
-
PhaseBio Announces Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab in NEJM Evidence
-
PhaseBio Names Jonathan Birchall as Chief Commercial Officer
-
PhaseBio (PHAS) Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Urgent Surgery or Experiencing
-
PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Urgent Surgery or Experiencing Unco
-
PhaseBio Reports Third-Quarter 2021 Financial Results and Recent Business Highlights
-
PhaseBio Pharmaceuticals to Host Investor Call to Discuss Interim Results from Pivotal REVERSE-IT Phase 3 Trial Presented at the American Heart Association Annual Meeting
-
PhaseBio Pharmaceuticals Inc. (PHAS) Announces Topline Results From Phase 2b Trial for Bentracimab
-
PhaseBio Announces Topline Results From Phase 2b Trial for Bentracimab
-
PhaseBio Announces Interim Analysis of REVERSE-IT Phase 3 Trial Accepted for Late Breaking Science Presentation at the American Heart Association Scientific Sessions 2021
-
PhaseBio Pharmaceuticals Inc. (PHAS) Appoints William D. Humphries to its Board; Justin Klein Steps Down
-
PhaseBio Appoints William D. Humphries to Board of Directors
-
PhaseBio Pharmaceuticals to Present at 23rd Annual H.C. Wainwright Global Investment Conference
-
PhaseBio Reports Second-Quarter 2021 Financial Results and Recent Business Highlights
-
PhaseBio Pharmaceuticals Achieves Enrollment Milestones Supporting Interim Analysis of REVERSE-IT Global Phase 3 Trial, Enabling Preparation of a BLA submission for Bentracimab for Reversal of Antipla
-
PhaseBio Pharmaceuticals (PHAS) and SFJ Pharmaceuticals Announce Approval of IND Application in China for Bentracimab
-
PhaseBio Pharmaceuticals and SFJ Pharmaceuticals® Announce Approval of IND Application in China for Bentracimab
-
PhaseBio Pharmaceuticals to Present at the William Blair Biotech Focus Conference 2021 on July 15
-
PhaseBio (PHAS) Announces European Licensing Agreement with Alfasigma S.p.A for Commercialization of Bentracimab
-
PhaseBio Announces European Licensing Agreement with Alfasigma S.p.A for Commercialization of Bentracimab
-
PhaseBio Highlights Real-World Healthcare Cost and Bleeding Cost Data Featured at the International Society for Pharmacoeconomic and Outcomes Research (ISPOR) Virtual 2021 Conference
-
PhaseBio Pharmaceuticals Inc. (PHAS) Real-World Bleeding and Surgery Data Featured at ACC
-
PhaseBio Highlights Real-World Bleeding and Surgery Data Featured at The American College of Cardiology's 70th Annual Scientific Session
-
PhaseBio Reports First-Quarter 2021 Financial Results and Recent Business Highlights
-
PhaseBio Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference
-
PhaseBio Reports Fourth-Quarter and Full-Year 2020 Financial Results and Recent Business Highlights
-
PhaseBio Pharmaceuticals to Participate in Upcoming Investor Conferences
-
 PhaseBio Pharmaceuticals to Host Virtual Investor and Analyst Day on March 15, 2021
-
Pre-Open Movers 07/17: (APDN) (OCN) (HMHC) Higher; (NIO) (NFLX) (ROKU) Lower (more...)
-
Pre-Open Stock Movers 05/28: (PHAS) (TGI) (DLTR) (TOL) (ALXN) (HTZ) (TWTR) (More...)